Location History:
- Hirakata, JP (1994 - 1997)
- Osaka, JP (1987 - 2003)
Company Filing History:
10 out of 260 
1 out of 73 
1 out of 198 Years Active: 1987-2003
Title: The Innovations of Akinori Sumi
Introduction
Akinori Sumi, an inventive mind based in Osaka, Japan, has made significant contributions to the field of biopharmaceuticals. With a remarkable portfolio of 12 patents, Sumi has been a driving force behind advancements in the purification processes of recombinant human serum albumin, a crucial component in various therapeutic applications.
Latest Patents
Among Akinori Sumi's latest inventions is a groundbreaking process for purifying recombinant human serum albumin (rHSA). This method involves heating a culture medium containing rHSA and the rHSA-producing host cells, followed by introducing the heated solution into a fluidized bed where adsorbent particles interact with the solution. This results in the recovery of a fraction containing rHSA that is of exceptional purity, as characterized by an A350/A280 ratio of below 0.015 when formulated into a 25% solution.
Another key patent focuses on a comprehensive process for producing and purifying human serum albumin derived from gene manipulation techniques. The method encompasses a series of ultrafiltration, heat treatments, and acid treatments, along with additional purification steps using chromatography and salting-out techniques. This ensures that the final human serum albumin product is substantially free from contaminants and retains high therapeutic efficacy.
Career Highlights
Over the years, Akinori Sumi has worked with prominent companies in the pharmaceutical industry, including The Green Cross Corporation and Mitsubishi Pharma Corporation. His expertise in protein purification technologies has paved the way for advancements in producing safe and effective biopharmaceutical products.
Collaborations
Sumi has collaborated with esteemed colleagues such as Takao Ohmura and Wataru Ohtani, working together to innovate and refine processes that contribute to the quality and efficiency of human serum albumin production. These professional relationships have likely fostered a collaborative environment that encourages ground-breaking advancements in the industry.
Conclusion
Akinori Sumi's contributions to the field of biopharmaceutical innovations through his patents demonstrate a commitment to enhancing the purity and efficacy of essential therapeutic proteins. His work reflects not only personal achievement but also significant impacts on health care advancements, showcasing how dedicated inventors can transform scientific knowledge into practical solutions.